{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+capsule&page=14", "query": { "intervention": "Active capsule", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 1413, "total_pages": 142, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+capsule&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+capsule&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T19:39:29.751Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02150967", "title": "A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Cholangiocarcinoma", "FGFR2 Gene Mutation" ], "interventions": [ { "name": "BGJ398 (infigratinib)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QED Therapeutics, a BridgeBio company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 143, "start_date": "2014-07-23", "completion_date": "2022-02-07", "has_results": true, "last_update_posted_date": "2023-07-03", "last_synced_at": "2026-10-23T19:39:29.751Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Los Angeles, California • San Francisco, California + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02150967" }, { "nct_id": "NCT02719392", "title": "A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Bipolar Disorder", "Bipolar Depression" ], "interventions": [ { "name": "N-acetylcysteine", "type": "DIETARY_SUPPLEMENT" }, { "name": "Minocycline", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG", "OTHER" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2017-08-09", "completion_date": "2026-07-20", "has_results": false, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-10-23T19:39:29.751Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02719392" }, { "nct_id": "NCT03812588", "title": "Contact: Developing New Clinical Management Strategies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Escitalopram", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New York State Psychiatric Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 29, "start_date": "2019-01-30", "completion_date": "2021-08-01", "has_results": true, "last_update_posted_date": "2022-04-21", "last_synced_at": "2026-10-23T19:39:29.751Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03812588" }, { "nct_id": "NCT04853368", "title": "Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cystic Fibrosis (CF)" ], "interventions": [ { "name": "ABBV-576", "type": "DRUG" }, { "name": "Galicaftor", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Navocaftor", "type": "DRUG" }, { "name": "ABBV-119", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2021-09-20", "completion_date": "2023-06-05", "has_results": true, "last_update_posted_date": "2024-07-16", "last_synced_at": "2026-10-23T19:39:29.751Z", "location_count": 22, "location_summary": "Mobile, Alabama • Los Angeles, California • Ventura, California + 19 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Ventura", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04853368" }, { "nct_id": "NCT04760613", "title": "CBD for Chronic Radicular Pain on Chronic Opioid Therapy (COT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Radiculopathy" ], "interventions": [ { "name": "Cannabidiol", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2022-02-03", "completion_date": "2023-06-07", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-23T19:39:29.751Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04760613" }, { "nct_id": "NCT02586623", "title": "Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Symptomatic Neurogenic Orthostatic Hypotension" ], "interventions": [ { "name": "Droxidopa capsules", "type": "DRUG" }, { "name": "Placebo capsules", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lundbeck A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 453, "start_date": "2016-02-11", "completion_date": "2022-09-09", "has_results": true, "last_update_posted_date": "2023-08-23", "last_synced_at": "2026-10-23T19:39:29.751Z", "location_count": 168, "location_summary": "Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 103 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02586623" }, { "nct_id": "NCT01970878", "title": "Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease (COPD)" ], "interventions": [ { "name": "GFF MDI (PT 003)", "type": "DRUG" }, { "name": "GP MDI (PT001)", "type": "DRUG" }, { "name": "FF MDI (PT005)", "type": "DRUG" }, { "name": "Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pearl Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 892, "start_date": "2013-11", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2017-03-17", "last_synced_at": "2026-10-23T19:39:29.751Z", "location_count": 110, "location_summary": "Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 107 more", "locations": [ { "city": "Andalusia", "state": "Alabama" }, { "city": "Anniston", "state": "Alabama" }, { "city": "Athens", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Jasper", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01970878" }, { "nct_id": "NCT02784535", "title": "Norepinephrine Transporter Blockade, Autonomic Failure (NETAF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neurogenic Orthostatic Hypotension" ], "interventions": [ { "name": "Atomoxetine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 48, "start_date": "2016-08-29", "completion_date": "2023-06", "has_results": true, "last_update_posted_date": "2023-09-13", "last_synced_at": "2026-10-23T19:39:29.751Z", "location_count": 2, "location_summary": "New York, New York • Nashville, Tennessee", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02784535" }, { "nct_id": "NCT00663208", "title": "A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "Daclatasvir", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 167, "start_date": "2008-05", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2015-10-14", "last_synced_at": "2026-10-23T19:39:29.751Z", "location_count": 7, "location_summary": "Anaheim, California • Cypress, California • New Haven, Connecticut + 4 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Cypress", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00663208" }, { "nct_id": "NCT06846320", "title": "Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Generalized Anxiety Disorder (GAD)" ], "interventions": [ { "name": "ABBV-932", "type": "DRUG" }, { "name": "Placebo for ABBV-932", "type": "DRUG" }, { "name": "Antidepressant Therapy (ADT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 315, "start_date": "2025-04-29", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-23T19:39:29.751Z", "location_count": 49, "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 43 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Colton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06846320" } ] }